




BioprocessOnline.com Editorial Themes

- ▶ Upstream process operations (APIs, assays, bioreactors, cell culture media, expression, fermentation, outsourced development, perfusion)
- ▶ Downstream process operations (chromatography, filtration, outsourced manufacturing, separation/purification, viral clearance)
- ▶ Regulatory considerations for early-stage biopharmas
- ▶ CMC foundations for the clinic & beyond
- ▶ CGMP: FDA quality baselines for biopharma
- ▶ Clinical design in a new era of regulatory flexibility
- ▶ Process considerations for emerging cell therapies
- ▶ Process considerations for emerging gene therapies
- ▶ Possibilities and pitfalls of outsourced biologics development
- ▶ New therapeutic modalities: where they fall on the biologic spectrum
- ▶ Biopharma market dynamics in a post-pandemic world
- ▶ Facilities design & bioprocess equipment selection
- ▶ Process intensification in practice
- ▶ Single use systems trends
- ▶ Biopharma supply chain: opportunities and constraints
- ▶ Biopharma 4.0: The marriage of computational science and biology
- ▶ IP & legal protections for new biopharma entities
- ▶ Profiles in biopharma leadership
- ▶ Early-stage biopharma financing and finance management
- ▶ Organizational development / startup management
- ▶ Sustainable sourcing: Ensuring self-sufficiency in APIs, process consumables & equipment
- ▶ Navigating government's role in the biologics market: Manufacturing, pricing, & more



MATT PILLAR
Chief Editor
BioprocessOnline.com





BiosimilarDevelopment.com Editorial Themes

- ▶ Cell-line & process development/formulation
- ▶ Analytical & clinical development strategies
- ▶ Bioprocessing trends
- ▶ Regulatory strategies
- ▶ Real-world evidence generation/collection
- ▶ Global regulatory reforms & guidance
- ▶ Switching/interchangeability
- ▶ Best practices for working with regulators
- ▶ Regulatory harmonization
- ▶ Global regulatory pathway development
- ▶ Government legislation & reimbursement policies
- ▶ Market access & commercialization strategies
- ▶ Market barriers
- ▶ The legal landscape
- ▶ Stakeholder education
- ▶ Payer policies & formulary management
- ▶ Real-world evidence initiatives
- ▶ Biosimilar business models



ANNA ROSE WELCH
Chief Editor

BiosimilarDevelopment.com



CellandGene.com Editorial Themes

- ▶ Developments in QA / QC
- ▶ Enhancements / best practices in process development
- ▶ Clinical trial design
- ▶ Next steps in “off-the-shelf” therapies
- ▶ Advancements in solid tumor medical research clinical trials
- ▶ Advancements in blood cancers clinical trials of new therapies or new combinations of therapies
- ▶ Scientifically validated and ethically responsible gene editing
- ▶ Cell and gene workforce education and training
- ▶ Clinical site onboarding for cell and gene clinical trials and for commercial-approved products
- ▶ Overall regulatory insights and hurdles
- ▶ Emerging platforms and technology
- ▶ Supply chain best practices
- ▶ Design and scalable production of gene transfer vectors
- ▶ Advancements in development of viral and non-viral gene delivery systems
- ▶ Financing future development
- ▶ Overcoming the biggest hurdles in gene therapy manufacturing (process development, safety testing, vector characterization, regulatory, etc.)
- ▶ Key components of the automation and industrialization of manufacturing
- ▶ Capacity constraints for current and future cell and gene therapies
- ▶ Finding the right contract service support
- ▶ Emerging strategies to support commercialization



ERIN HARRIS
Chief Editor
CellandGene.com

Life Science Leader Editorial Themes

- ▶ AI & machine learning in drug development
 - ▶ Best practices / strategies for working with regulators
 - ▶ Market access & commercialization strategies
 - ▶ Challenges of emerging biopharma
 - ▶ Clinical trial planning & execution trends
 - ▶ Corporate culture development
 - ▶ Diversity & inclusion management strategies
 - ▶ Finance / funding strategies
 - ▶ Hot legal-related issues in pharma
 - ▶ Profiles of top pharma / biopharma executives
 - ▶ IP / patent protection
 - ▶ Companies to watch / emerging platforms & technology
 - ▶ Leadership lessons
 - ▶ Life science region profiles
- ▶ Outsourced manufacturing trends / activities
 - ▶ Patient diversity in clinical trials
 - ▶ Pharma / biopharma entrepreneurs
 - ▶ Startup / emerging biopharma challenges
 - ▶ Unique business / growth strategies
 - ▶ Women shaping the life sciences industry



ROB WRIGHT
Chief Editor
Life Science Leader





OutsourcedPharma.com Editorial Themes

- ▶ How to select CDMOs
 - ▶ Managing CDMO relationships
 - ▶ CDMO-drug sponsor business/relationship models
 - ▶ Drug development strategies/challenges
 - ▶ Scale up and manufacturing strategies/challenges
 - ▶ Whether or not to use a CDMO (build vs. buy)
 - ▶ Support services (testing, analytical, regulatory, etc.)
- ▶ New drug categories/modalities, new equipment and new facilities
 - ▶ U.S. domestic resurgence of drug development and manufacturing



LOUIS GARGUILO
Chief Editor
OutsourcedPharma.com





PharmaceuticalOnline.com Editorial Themes

- ▶ Implementing advanced manufacturing technology (automation, robotics, AI, Big Data, etc.)
- ▶ Designing and constructing next-generation facilities and processes (flexible, modular, decentralized, continuous, etc.)
- ▶ Managing and securing a post-COVID supply chain (re/nearshoring, remote audits, resilience, etc.)
- ▶ Improving quality systems and culture (data integrity, human performance, risk management, etc.)
- ▶ Staying ahead of the regulatory and compliance curve (understanding new US and OUS regulations/standards, learning from enforcement activities, etc.)



JIM POMAGER
Executive Editor

PharmaceuticalOnline.com

